T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...

Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny ...

Corvus Pharmaceuticals, Inc. jumps 165% on Phase 1 soquelitinib atopic dermatitis data; learn key efficacy, funding, and ...

Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15.

Daiichi Sankyo receives Prime Minister’s Award for Japan Medical Research and Development Grand Prize: Tokyo Tuesday, January 20, 2026, 17:00 Hrs [IST] Daiichi Sankyo has receiv ...

As we age, the immune system gradually declines in function, leaving the body more vulnerable to disease. Scientists have discovered a new way to rejuvenate a key component of immune function, ...

AstraZeneca will buy AbelZeta Pharma’s 50% share of development and commercialization rights in China for a CAR-T therapy for ...

SAN DIEGO and SUZHOU, China, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company ...

Cipla partners with ImmunoAct to introduce India’s first CAR-T cell therapy in Africa, enhancing accessible cancer treatment ...